P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

NCT06468033 | Recruiting Phase 3 DMC FDA Drug

• 1 other identifier: A23-302
• Study Type: interventional
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phase 3 double-blind clinical trial arm to test Ropeginterferon alfa-2b (P1101) in adult patients with Primary Myelofibrosis (PMF) at early stage or low to medium risk. Participants will receive the study drug/placebo bi-weekly and have an assessment visit every 4 weeks. The ratio of study drug to placebo group is 2:1.

Conditions

Primary Myelofibrosis; Myeloproliferative Neoplasm

Keywords

P1101; Primary Myelofibrosis; PMF; Ropeginterferon; PharmaEssentia; Myeloproliferative neoplasms; MPN; Pre-fibrotic; Low or Intermediate-1 Risk

Outcome Measures

Primary Outcomes (6)

• Number of Participants with Platelet count equal or less (≤) 400 × 10^9/L

  Platelet count ≤400 × 10\^9/L is one of the criteria for clinically relevant complete hematologic response (CrCHR).

  80 weeks

• Number of Participants with White Blood Cells (WBC) count equal or less (≤) 10 × 10^9/L

  White Blood Cells (WBC) count ≤10 × 10\^9/L is one of the criteria for clinically relevant complete hematologic response (CrCHR).

  80 weeks

• Number of Participants with Hemoglobin (Hgb) equal or greater (≧) 10.0 g/dL

  Peripheral blood: Hemoglobin (Hgb) ≧ 10.0 g/dL is one of the criteria for clinically relevant complete hematologic response (CrCHR).

  80 weeks

• Number of Participants absence of major thrombotic events

  The absence of major thrombotic events during the observation time frame is one of the criteria for clinically relevant complete hematologic response (CrCHR).

  80 weeks

• Number of Participants with no progression to secondary acute myeloid leukemia (AML).

  The absence of progression to secondary acute myeloid leukemia (AML) is one of the criteria for clinically relevant complete hematologic remission (CrCHR).

  80 weeks

• Number of Participants with no progression on the Total Symptom Score (TSS)

  The TSS score is utilized to evaluate clinical symptoms, which is based on the MFSAF Total Symptom Score (TSS) form v4.0. No progression is defined as: * The participants who still have a TSS score equal to or less than (≤) 10 If the baseline score is ≤ 10. * The participants with a TSS score no increase than 50% If the baseline score is greater than (\>) 10.

  80 weeks

Study Arms (2)

Ropeginterferon alfa-2b (P1101)

EXPERIMENTAL

Ropeginterferon alfa-2b (P1101) is administrated subcutaneously (SC) every two weeks (± 3 days) until 80 weeks.

Biological: Ropeginterferon alfa-2b

Placebo control

PLACEBO COMPARATOR

Placebo is administrated subcutaneously (SC) every two weeks (± 3 days) until 80 weeks.

Other: Placebo

Interventions

Ropeginterferon alfa-2b BIOLOGICAL

Pre-filled Syringe. Dosage: up to 500mcg

Also known as: P1101

Ropeginterferon alfa-2b (P1101)

Placebo OTHER

Placebo is a look-alike substance with the intervention (Ropeginterferon alfa-2b) that contains no active drug.

Placebo control

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female patients aged ≥18 years at the time of signing the informed consent form;
• Patients with pre-fibrotic/early PMF (Pre-PMF) or overt primary myelofibrosis at low to intermediate-1 risk according to DIPSS plus, diagnosed according to WHO 2016 or 2022 classification;
• With good liver function at screening, which is defined as total bilirubin ≤1.5 × upper limit of normal (ULN), international normalized ratio (INR) ≤1.5 × ULN, albumin \>3.5 g/dL, alanine aminotransferase (ALT) ≤2.0 × ULN, and aspartate aminotransferase (AST) ≤2.0 × ULN;
• Hgb ≥10.0 g/dL at screening;
• Neutrophil count ≥1.0 × 10\^9/L at screening;
• Creatinine clearance rate ≥30 mL/min at screening (according to the Cockcroft-Gault formula);
• Females of childbearing potential, as well as all women \<2 years after the onset of menopause, must agree to use an acceptable form of birth control until 60 days following the last dose of the study drug, and females must agree to not breastfeed during the study;
• Written informed consent obtained from the subject and ability for the subject to comply with the requirements of the study.

You may not qualify if:

• Any known contraindications to interferon α or hypersensitivity to interferon α;
• Patients with prior interferon therapy having poor tolerability or lack of efficacy to the previous interferon therapy per investigator\'s judgement;
• Patients with an ongoing cytoreduction (e.g., HU or IFN-α) at the time of screening if, in the Investigator's opinion, randomizing them into the placebo arm will lead to immediate rebound increase of peripheral blood counts and thus may jeopardize their health status;
• With severe or serious diseases that, in the Investigator's opinion, may affect the patient's participation in this study;
• History of major organ transplantation;
• Pregnant or breastfeeding women;
• Patients with any other diseases that will affect the study results or may weaken the compliance to protocol per the Investigator's judgment;
• Use any investigational drug \<4 weeks prior to the first dose of study drug, or not recovered from effects of prior administration of any investigational drug.
• Eligible for JAK inhibitor therapy at screening.

Sponsors & Collaborators

• PharmaEssentia: lead

Study Sites (1)

University of Yamanashi Hospital

Chūō, Yamanashi, 409-3898, Japan

RECRUITING

MeSH Terms

Conditions

Primary Myelofibrosis; Myeloproliferative Disorders

Condition Hierarchy (Ancestors)

Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Toshiaki Sato, MD/PhD

  PharmaEssentia JP

  STUDY DIRECTOR

Central Study Contacts

Sandy Kan

CONTACT

+886-2-26557688; sandy_kan@pharmaessentia.com

Aypiin Shen

CONTACT

+886-2-26557688; aypiin_shen@pharmaessentia.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Double-Blind
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 10, 2024
• First Posted: June 21, 2024
• Study Start: July 18, 2025
• Primary Completion (Estimated): September 30, 2027
• Study Completion (Estimated): September 30, 2028
• Last Updated: August 13, 2025

Record last verified: 2025-08

Locations

JP (1)